BR100 Increased By (0.86%)
BR30 Increased By (1.11%)
KSE100 Increased By (0.82%)
KSE30 Increased By (0.93%)
AGHA 6.46 Increased By ▲ 0.08 (1.25%)
BECO 4.38 Increased By ▲ 0.03 (0.69%)
BML 62.30 Decreased By ▼ -0.25 (-0.4%)
BOP 31.38 Decreased By ▼ -0.01 (-0.03%)
CNERGY 11.83 Increased By ▲ 0.10 (0.85%)
CSIL 5.85 Decreased By ▼ -0.06 (-1.02%)
FCCL 61.99 Increased By ▲ 0.28 (0.45%)
FFL 14.95 Increased By ▲ 0.16 (1.08%)
FNEL 1.34 Increased By ▲ 0.10 (8.06%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.84 Decreased By ▼ -0.06 (-1.02%)
LOTCHEM 24.97 Increased By ▲ 0.28 (1.13%)
MLCF 106.00 Increased By ▲ 2.07 (1.99%)
NBP 174.90 Increased By ▲ 1.58 (0.91%)
NCPL 52.10 Increased By ▲ 0.27 (0.52%)
NPL 54.97 Increased By ▲ 0.94 (1.74%)
OGDC 320.19 Increased By ▲ 4.32 (1.37%)
PACE 9.31 Increased By ▲ 0.05 (0.54%)
PAEL 35.84 Increased By ▲ 0.26 (0.73%)
PIBTL 14.20 Increased By ▲ 0.54 (3.95%)
PPL 229.12 Increased By ▲ 3.05 (1.35%)
PRL 81.71 Increased By ▲ 1.43 (1.78%)
PTC 47.33 Increased By ▲ 0.69 (1.48%)
SSGC 23.96 Increased By ▲ 0.14 (0.59%)
TBL 9.26 Increased By ▲ 0.02 (0.22%)
TELE 7.57 Increased By ▲ 0.02 (0.26%)
TPL 24.50 Decreased By ▼ -0.04 (-0.16%)
TPLP 13.10 Increased By ▲ 0.11 (0.85%)
TREET 26.02 Increased By ▲ 0.04 (0.15%)
TRG 53.75 Increased By ▲ 0.42 (0.79%)
Business & Finance

BioNTech to look into possible dividend next year

  • BioNTech would not look into a proposal for any dividend before next year's annual shareholder meeting.
  • Vaccine supply deals lined up for this year alone are worth 12.4 billion euros ($15.1 billion) in revenue for BioNTech.
Published Updated
By

FRANKFURT: BioNTech, the Pfizer partner set to earn billions from their COVID-19 vaccine, said it would consider paying out a dividend next year and that its focus this year was on spending on its pharmaceutical development projects.

BioNTech would not look into a proposal for any dividend before next year's annual shareholder meeting, Finance Chief Sierk Poetting told shareholders.

"Our strategic priority for 2021 is the reinvestment of capital," Chief Executive Ugur Sahin said at the virtual annual shareholder meeting, adding that funds would go its development efforts in various therapy areas and technologies.

BioNTech in December became the first Western company to win preliminary approval for its coronavirus vaccine.

Vaccine supply deals lined up for this year alone are worth 12.4 billion euros ($15.1 billion) in revenue for BioNTech, it said in May. It repeated on Tuesday that more supply contracts were on the cards.

CEO Sahin also reiterated that he currently saw no need to change the make-up of the Comirnaty vaccine as it still appears to protect against newly circulating coronavirus variants of concern, which are more contagious than predecessor viruses.

Comments

Comments are closed for this article.